Therapeutic Apheresis, Immunosuppression, and/or Human Monoclonal Antibodies in Cardiology

Review Article | DOI: https://doi.org/10.31579/2692-9759/145

Therapeutic Apheresis, Immunosuppression, and/or Human Monoclonal Antibodies in Cardiology

  • Rolf Bambauer 1*
  • Ralf Schiel 2
  • Octavio J Salgado 3
  • Richard Straube 4

1 Institute for Blood Purification and University of Saarland, Germany.

2 Clinic for Metabolic Diseases, Medigreif Inselklinik, Heringsdorf, Germany.

3 School of Medicine, Universidad Catolica de Cuenca, Ecuador.

4 INUSpherese®, INUS Medical Center; Cham Tagesklinikum, Germany. 

*Corresponding Author: Rolf Bambauer, Institute for Blood Purification and University of Saarland, Germany.

Citation: Rolf Bambauer, Ralf Schiel, Octavio J Salgado, and Richard Straube, (2024), Therapeutic Apheresis, Immunosuppression, and/or Human Monoclonal Antibodies in Cardiology, Cardiology Research and Reports, 6(6); DOI:10.31579/2692-9759/145

Copyright: © 2024, Rolf Bambauer. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 16 October 2024 | Accepted: 24 October 2024 | Published: 05 November 2024

Keywords: Idiopathic dilated cardiomyopathy; coronary heart disease; acute myocardial infarction; heart transplant rejection; therapeutic plasma exchange; immunoadsorption; extracorporeal photopheresis; creative reactive protein apheresis

Abstract

Therapeutic apheresis is an essential supportive treatment for severe and refractory diseases with or without immunologic origin. The advantages of therapeutic plasma exchange with hollow fiber membranes include a complete separation of the corpuscular components from the plasma and increased efficacy due to an elevated blood flow rate. Therapeutic apheresis has been shown to significantly improve the prognosis of idiopathic dilated cardiomyopathy, coronary heart disease, acute myocardial infarction and heart transplant rejection. This therapy is indicated as first- or second-line therapy in combination with immunosuppression, and/or human monoclonal antibodies and others. The immunologic and molecular biology of the different cardiologic diseases are mentioned and discussed in relation to rationale for apheresis therapy and its place with other modern therapy. The pathogenetically backgrounds are demonstrated in these cardiologic diseases, in which they are clarified.  Therapeutic apheresis using hollow fiber membranes, and/or semi-, or selective columns is a safe and highly effective method for elimination of autoantibodies, immune complexes, inflammatory moderators, paraproteins and other toxins from blood, resulting in rapid clinical improvement in cardiologic diseases.  The guidelines of the American Application Committee of the American Society for Apheresis are cited for cardiologic disease, which could be treated with therapeutic apheresis, immunosuppression and human monoclonal antibodies.     

Introduction

As an essential supportive therapy, therapeutic apheresis (TA) offers considerable benefits for patients with severe or refractory to conservative therapy. Therapeutic apheresis has shown to significantly improve the prognosis of these diseases. The utilization of hollow fiber modules enables the complete separation of cellular elements from the plasma, while concurrently reducing thrombocyte damage in comparison to the employment of centrifuges [1]. During the treatment with hollow fiber modules is important to keep the blood levels of antibodies or other pathogenic substances on a very low level over a long time during the treatment, in which the pathogenic substances that should be eliminated could enter the intravascular space and could be then removed by hollow fiber modules [2]. 

A multitude of technological, economic, and social factors have impact on the clinical practice of apheresis [3]. Double filtration and adsorption technologies with special columns allow a selective removal of autoantibodies, toxins, and other pathologic substances from blood without any substitution solution [4].

With more than 25 years` experience of TA in various diseases such as nephrology, hematology, neurology, dermatology diseases and others, we give an overview of the different TA methods used in cardiology [1, 2, 5, 6]. In particular, autoimmune diseases in which circulating autoantibodies play a harmful role, the removal of these immunoglobulins can have a beneficial effect on the course of the disease. With immunoadsorption (IA) by using Ig columns, the elimination of circulating autoantibodies and immune complexes (IC) can lead to an improvement of the disease [4].

 The development and maintenance of autoimmune diseases may be influenced by circulating immunoglobulins. Dilated cardiopathy (DCM) is an autoimmune disease caused by the presence of circulating autoantibodies directed against β1 adrenoceptor. Consequently, patients with DCM may be benefit from IA and immunosuppression [7, 8].

Dyslipoproteinemia plays a key role in the pathogenesis of atherosclerosis of atherosclerosis and coronary heart diseases (CHD). Elevated low-density lipoprotein cholesterol (LDL) and/or Lipoprotein (a) (Lp(a)) are well established risk factors for cardiovascular disease (CVD) [6]. There is a mutual effect between high LDL, low HDL, and hypertriglyceridemia. Despite substantial advancements in diagnostics, drug therapy, and cardiosurgical procedures, arthrosclerosis with myocardial infarction, stroke, and peripheral vascular disease still maintains its position at the top of morbidity statistics in industrialized nations [9-11]. The drug therapies include besides statins and 3.hydroxy-3-methylgluraryl-coenzyme A (HMG-CoA)-reductase inhibitors, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9 inhibitors), and lipoprotein apheresis (LA), which is safe and can control lipid levels [11]. 

C-reactive protein (CRP) is a marker of inflammation that is also elevated in acute myocardial infarction (AMI), too. It mediates tissue damage in AMI thus worsening the prognosis [12]. In addition to acute-phase proteins, CRP and other substances are deposited in the necrotic center of the infarcted myocardium [13]. This represents one of the mechanisms through which the immune system further exacerbates myocardial necrosis, mediating secondary damage to the myocardium [14]. Therefore, the demand is that the selective depletion or apheresis of these proinflammatory mediators in AMI, especially CRP, may prove beneficial in mitigating myocardial necrosis and consecutively improve outcomes. A developed specific CRP adsorbers (Pentacor GmbH; Henningsdorf, Germany), which contains a phosphocholine derivate as ligand for CRP, is capable of selectively CRP from plasma with a high efficiency [15]. 

In select patients with end-stage heart failure the heart transplantation is the gold standard therapeutic options. Annually, thousands of heart transplants are performed worldwide. However, successful long-term outcomes of heart transplantation can be disturbed by immune-mediated injection of the cardiac allograft, as acute cellular rejection, antibody-mediated rejection, and allograft vasculopathy [16]. 

In addition to immunosuppression (IS), therapeutic plasma exchange (TPE), IA, and/or human monoclonal antibodies (HMA), extracorporeal photopheresis (ECP) are indicated in acute and chronic rejection of solid organ transplantation. Extracorporeal photopheresis, a cellular immunotherapy, intails the collection and treatment of white blood cells contained in the buffy coat with a photoactive psoralen compound, followed by irradiation with ultraviolet A light [16].

All these mentioned heart diseases require TA, IS with steroids and/or cytotoxic agents, and/or HMA. The therapy is most individually tailored to the specific needs of the patients in the greatest possible degree [17, 18]. The TA methods, which are used in cardiology are TPE, IA, LA, ECP, and CRP apheresis. In the present review, the authors sought to provide an overview of the pathogens aspects indicating that TA, IS and/or HMA may serve as be a supportive therapy in these severe cardiologic diseases. The Apheresis Application Committee (AAC) of the American Society for Apheresis (ASFA) is cited for these disorders in which TA, IS and/or HMA are indicated. (Table 1).

Idiopathic Dilated Cardiomyopathy (IDCM) 

Idiopathic dilated cardiomyopathy is a disease consisting of left ventricular dilation and contractile dysfunction accompanied by impairment of multiple β-adrenergic receptor function [19, 20]. The disturbed β-adrenergic receptors function may be based on an elevated sympathetic tone observed in patients with dilated cardiomyopathy. The tissue concentration of norepinephrine is decreased and plasma concentration of this transmitter is elevated providing evidence of sympathetic activation. Such an increased sympathetic tone results in down-regulation of the β-adrenoceptor-mediated signal transduction cascade, the induction of fetal proteins, and markers of hypertrophy [21]. Another possibility is that such prolonged adrenergic stimulation induces metabolic and electrophysiologic disturbances in the myocardium and is responsible for tachyarrhythmia and sudden death [22]. 

The blood of patients with IDCM contains circulating antibodies directed against β1 adrenoceptor [23]. The number of β1-adrenoceptors and the β-adrenergic responsiveness are decreased in patients with IDCM. The fact that the anti-β1-adrenoceptor antibodies could play a role in the pathogenesis of IDCM has been demonstrated in patients with end-stage ICDM who were supported by a ventricular assist device [19].

The incidence of IDCM varies between 5 to 8 patients per 100,000 of the population, and in the United States on average 36 patients per 200,000 of the population [24]. The prognosis is worst for patients with the lowest ejection fractions of severe diastolic dysfunction [20]. The treatment of ICDM comprises medications to improve survival and reduce hospitalization, such as angiotensin converting enzyme inhibitors and β-blockers. Other therapies include enrolment in a multidisciplinary heart failure service, and device therapy for arrhythmia management and sudden death prevention [17]. Patients who are refractory to medical therapy may benefit from an implantable defibrillator and/or heart transplantation [20, 25]. 

In animal and receptor studies, autoantibodies have been identified that contribute to the progressive deterioration of cardiac function in a subset of patients with IDCM [26]. These antibodies, initially detected in patients with Chagas´ disease, were present in 80 percent of patients with end-stage IDCM and all patients required mechanical cardiac support [27]. Cardiac function recovered to near-normal values concomitant with gradual disappearance of β1-autoantibodies in 20 percent of the mechanically supported patients [27]. 

The hypothesis postulates that cardiac antibodies play an important role for the induction, maintenance, and progression of IDCM and that their elimination through IgA IA should improve or at least stabilize the function of the heart in a analogous manner to other autoimmune diseases. This was shown in short-time effects with IgA IA treatments in 7 patients with IDCM by Wallukat et al. [28]. The β1-autoantibodies, a part of the IgG fraction, were used as a marker for autoantibody presence to identify patients who might benefit from IA. 

The echocardiographic evaluation of left ventricular ejection fraction (LVEF) and internal diameters were chosen to determine cardiac performance, and the New York Heart Association (NYHA) functional class was correspondingly assessed. Immunoadsorption offers an effective and low-risk treatment that has the potential to postpone or even avoid heart transplantation, which otherwise would be the midterm perspective for patients with IDCM. The removal of β1-autoantibodies has been proposed as a potential mechanism for the improvement of the LVEF in ICDM [27].

Patients with IDCM were treated with adsorber against immunoglobulins (Miltenyi Biotec, Germany), the Corafin column (Affina, Germany), the protein-A IA (Fresenius, Germany), or special columns containing a combination of synthetic peptides which are binding antibodies which inhibits the β1-adrenergic receptors of the heart muscle. The IA treatments were conducted on 5 – 9 consecutive days with or without IgG substitution over 4 weeks (1 cycle; in total 4 cycles). Several authors, who treated patients with IDCM with different IA systems and IS, found improvement in short-term hemodynamics as well as long-term follow-up with severe IDCM [29-36].

Therapeutic apheresis, immunosuppressive therapy and intravenous immunoglobulins (IVIG) have been demonstrated to improve both cardiac function and daily activities in patients with IDCM and arrhythmias resulting from myocarditis, and may be an effective treatment. Immunoadsorption represents viable alternative to the use of immunosuppressive medication or the reduction of high doses of it, and is a safe method (33, 34). The AAC of the ASFA has given the IDCM the category III with recommendation grade (RG) 2B and 2C respectively for TPE and IA (17, 18) (Table 1). 

Table 1: Therapeutic Apheresis in Cardiology (17, 18)

 Category 

Recommen-

dation grade

TA-modality 

Treatment volume

(TPV)

Replacement solutionFrequency
Idiopathic dilated cardiomyo-pathy (IDCM)

 

III

III

 

2B

2C

 

TPE

IA-Protein-A

 

1-1.5

1-1.5

 

5% HA

---

 

daily or every other day

Coronary heart disease and dysliproteinemia

(CHD)

 

II

 

1A

TPE,

selective separation

methods

1-1.5

---

5% HA

---

daily or every other day
Acute myocardial infarction (AMI) 

 

---

 

---

 

---

 

---

 

---

 

---

Heart transplant rejection

II (desensitization)

III (AMR)

 

II (cellular/recurrent rejection)

II  

(rejection prophylaxis)

1C

 

2C

1B

 

 

2A

TPE

 

TPE

ECP

 

 

ECP

1-1.5

 

1-1.5

1-1.5 L

Blood

 

1-1.5 l

blood

5% HA

 

5% HA

---

 

 

---

daily or every other day

 

weekly or every 2-8 weeks for several months

(Category I: accepted for TA as first-line therapy; Category II: accepted for TA as second-line therapy; Category III: not accepted for TA, decision should be individualized)

TPE: therapeutic plasma exchange, IA: immunoadsorption, ECP: extracorporeal photopheresis, 5%HA:  human albumin electrolyte solution

Coronary Heart Disease (CHD) and Dyslipoproteinemia                   

Dyslipoproteinemia plays a key role in the pathogenesis of atherosclerosis and CHD. Elevated LDL, reduced HDL, and hypertriglyceridemia affect each other. Despite progress in diagnostics, drug therapy, and cardiosurgical procedures, atherosclerosis with myocardial infarction, stroke, and peripheral vascular disease continues to present a significant burden in industrialized nations, as evidenced by its prominence in morbidity statistics [37, 38]. Widely accepted established risk factors are smoking, arterial hypertension, diabetes mellitus, central obesity, hyperlipidemia for atherosclerosis [39]. 

The vascular endothelium is the largest endocrine, paracrine and autocrine participants in the regulation of numerous homeostatic vascular functions [40]. Endothelial cells are capable of sensing alterations in hemodynamic forces such as pressure and shear stress, as well as circulating and locally formed vasoactive substances released by blood cells. From these stimuli, endothelial cells synthesize and release biologically active substances such as nitride oxide (NO), prostacyclin (PGI2), endothelium-derived hyperpolarizing factor (ED-HF), endothelin’s, prostaglandin H2 (PGH2), thromboxane A2, heparin sulfate, transforming growth factor, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), tissue plasminogen-activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), oxygen free radicals, and others [40]. These substances modulate vascular tone through their relaxing and contracting actions, as well as vascular structure through production of growth-promoting and growth-inhibiting factors. In the development of endothelial dysfunction in dyslipoproteinemia is important a decrease in the synthesis of endothelial NO and an increase in its active radicals, causing 

modification of low-density lipoprotein and their deposition in the vascular endothelium [41]. The endothelium also regulates hemostasis and thrombosis through the expression of chemotactic and adhesion molecules [42]. 

Elevated lipid concentration in the blood lead to their accumulation in the intima of arteries, resulting in the development of atherogenic plaques, which are accompanied by changes in vessel tone and endothelium regulation [43, 44]. High levels of LDL increase the risk of the development and progression of CHD [38].

Lipoprotein (a), as an atherogenic substance is very similar to LDL, and Lp(a) contains Apo(a), which is very similar to plasminogen, enabling Lp(a) to bind fibrin clots. The binding of plasminogen is prevented and fibrinolysis obstructed, and has 6 different Lp(a) phenotypes S4, S3, S2, S1, B, and F. [45, 46]. The isoforms S2; S1, B, and F are linked to CHD, and patients with premature CHD showed the highest the highest Lp(a) levels as well as the isoforms S2, S1, B, and F [47]. A number of mechanisms have been postulated, as blocking of plasminogen, a binding site on fibrin clots, interaction with other coagulation proteins, and hepatic growth factor [38, 48]. In summary, potentially modifiable CHD risk factors are systemic inflammation, diabetes mellitus, low-density lipoprotein, high triglycerides, remnant lipoproteins, Lp(a), and vascular dysfunction [49,50].

A further risk factor for accelerated atherosclerosis is the widespread high level of homocysteine, which are particularly prevalent in dialysis patients [51]. Homocysteine is a independent risk factor, and is a sulfur amino acid and produced int the metabolism of methionine [52]. Vitamins are important cofactors for the enzymes in the methionine metabolism such as folic acid, vitamin B 12 for remethylation pathway, and vitamin B 6, or pyridoxine for the transculturation pathway. The kidneys are responsible for the removal of up to 70 percent of plasma homocysteine. The therapy with Vitamins B 6 and B 12 are sufficient in most dialysis patients [53]. 

Table 2 illustrate the pharmacological treatments for dyslipoproteinemia in CHD, which is the main causes of death in the mortality statistics of the industrial nations. All HMG-CoA-reductase inhibitors, which can be combined with other lipid reducers, were found to cause a variety of adverse effects liked diarrhea, obstipation, other gastrointestinal diseases, myositis, rhabdomyolysis, and others were observed [54]. Ezetimibe is another cholesterol absorption inhibitor that prevents the absorption of cholesterol by inhibiting the passage of cholesterol of dietary and biliary origin across the intestinal wall. It is well tolerated and can be combined with HMG-CoA reductase inhibitors, and has been demonstrated to be highly efficacious [55, 56].

Drugs

Cholesterol

(%)

LDL (%)HDL (%)

Triglycerides 

(%)

Ion exchanger-10 - -30-10 - -30+0 - +10+0 - -20
Fibrates-10 - -25-5 - 25 +5 - +25-25 – 260
Nicotinic acid -10 - -25-5 - -25+5 - +25-40 - -60
Probenol-5 - -5-5 - -25+5 - +15-40 - -60
HMG-CoA reductase inhibitor-20 - -40-25 - -40+0 - +15 -10 - -20
Ezetimibe-15 - -20-15 - -25+2.5 - +5-6 - -14

Table 2: The effects of maximum dosage of different lipid reducers [38, 57, 58]

Nevertheless, the combination HMG-CoA-reductase inhibitor, with ezetimibe or other lipid reducers, a LDL reduction of up to 50 percent of the original concentration can be achieved. In a considerable number of patients, this appears to be a quite effective approach (Table 2).

With the semi-selective and selective extracorporeal TA techniques all severe forms or therapy-resistant forms can be effectively treated [59]. In Table 3 are summarized the semi-selective and selective LDL-methods with their effectiveness of different substances.   

 

Cascade filtration

2500-3000

ml plasma

(%)

Immuno-

adsorption

4000-5000

ml plasma

(%)

Heparin-

induced LDL preci-

pitation (HELP)

2500-3000

ml plasma

(%)

LDL adsorption,

Liposorber

2500-3000

ml plasma

(%) 

LDL-hemoper-

fusion

(DALI)

1.6 blood 

volume

(%)

LDL-

hemoper-

fusion

(Lipo-sorber D)

1.5 blood

Volume

(%)

Cholesterol35 503050456055
LDL30 - 45354533 - 4060 - 7560 - 75
HDL35 - 502010 - 20---16 - 295 - 13
Lp(a)60 - 7060466060 - 7560 - 75
Triglycerides60606070ca 40ca 66
Fibrinogen5010 - 2050301620 - 40
IgM3510 - 20------2114
IgA5510 - 20------------
Factor VIII---10 - 2010 - 2020------
C 3------50---------
C 4------50---------
Plasminogen------50---------

Table 3: Effectiveness of the different LA methods (reduction in percent of original concentration in blood (38, 59, 60).

All the methods mentioned above are effective, safe, and well tolerated. The average LDL cholesterol concentration can be reduced to approximately 50-60 percent of the original values, with weekly or biweekly treatments. The cholesterol concentration increases after each apheresis session, but does not return to the original concentration. Following a few sessions, the levels return to equilibrium. The increase after apheresis treatment must be slowed down with a combination of TA and HMG-CoA-reductase inhibitor and ezetimibe, or others [60]. The primary aim in reducing cholesterol concentration is to prevent the development and progression of atherosclerosis. The lowering of cholesterol from 400 mg/dL to 200 mg treatment could almost double a patient´s life expectance [61]. The TA treatment in indicated in homozygous and severe heterozygous or other forms of hypercholesterolemia which failed by conservative therapy life-long or until other therapy technologies such as HMAs or gene therapy are available for everyone. The AAC of the ASFA has given the CHD the category II and the RG 1A for TPE, respectively selective separation methods [17, 18] (Table 1)   

Proprotein convertase subtilisin/kexin type 9 is involved in cholesterol metabolism that is enzymatically inactive following secretion. Plasma PCSK9 concentration decreases with fasting and increases following meals in healthy humans [62]. The PCSK9 has an important regulator of cholesterol metabolisms. The PCSK9-inhibitors showed favourable outcomes in terms of lipid lowering, with a 50 to 60 percent improvement in original LDL-levels [63,64]. With evolocumab and alirocumab, two PCSK9-inhibitors, and other statins, and/or LA, all severe hypercholesterolemia with cardiovascular disease are treatable. 

However, after a long period of diet and maximum lipid lowering drugs therapy, or refractory to drug therapy, LA is indicated. The prospective utilization of HMA, including evolocumab or alirocumab, may be expedited by the identification of techniques to augment antibody expression [65]. Nevertheless, the number of patients with extremely elevated Lp(a) who need the extracorporeal therapy or the HMA- or gene therapy will increase. Therefore, larger studies must be showing which methods the LA or the PCSK9 inhibition in combination or alone would be preferred [66, 67].   

Acute Myocardial Infarction (AMI)

C-reactive protein is marker of inflammation. It is less documented, however, that CRP mediates secondary damage of the myocardium after AMI [12]. C-reactive protein is an acute-phase mediator which activates the classical complement pathway, resulting in the elimination of pathogens or reversible damaged or dead body cells [68]. The presence of inflammatory markers, such as CRP, can serve as an indicator for the potential development of acute coronary syndrome (ACS) development. Inflammation is a physiological reaction in which fibrosis is induced to facilitate the healing of tissue, an excessive inflammatory response in this process intensifies the necrosis of infarcted myocardium and inhibits healing processes, such as angiogenesis and the replacement of collagens fibers [69]. In patients with AMI, circulating levels of CRP increase beginning six hours after the onset of ischemia, reaching their peak levels between 24 and 72 hours later. The magnitude of CRP rise is a prognostic marker of one-year outcomes post myocardial infarction [70]. 

As a result of trauma, inflammation, or infection, CRP is synthetized and secreted into the blood by hepatic cells [66]. Proinflammatory cytokines, interleukin-6 (IL-6), interleukin-1 (IL-1), and tumor necrosis factor α (TNF-α) induce CRP expression in these ways [71]. The elevated CRP initiates the phagocytosis via the activation of the classical pathway, up to C4 [68, 72]. In the necrotic center of the infarcted myocardium, acute-phase proteins, CRP and secretory phospholipase A2 type IIa are deposited [73]. In this way, the immune system exacerbates myocardial necrosis, mediating secondary damage to the myocardium (68, 70). The hypothesis that can be derived from these observations is that a selective depletion or selective apheresis of these proinflammatory mediators in AMI may help mitigate myocardial necrosis and consecutive improve. 

C-reactive protein is the prototype of human acute-phase proteins and a marker of inflammation, it has also been demonstrated to mediate tissue damage in various conditions including ischemic tissue injury, autoimmune disease, etc. [68] C-reactive protein is not only a marker of inflammation but also an active pro-inflammatory protein. In patients presenting with a ST-elevation myocardial infarction, CRP levels are associated with larger infarct size, transmural extent, and poor function of left ventricle, and independently predict 30-day mortality [74]. The elimination of CRP from plasma may potentially be a broadly applicable therapeutic strategy.

In recent years, a specific CRP adsorber has been developed which allows efficient lowering of CRP levels and may ultimately lead to improve survival outcomes [12]. The CRP adsorber, an agarose-based resin, which contains a phosphocholine-derivate as ligand for CRP and is capable of selectively depleting CRP from plasma with an efficiency of up to 94 percent [15, 68]. The CRP adsorber is introduced in a primary plasma separation method. The CRP adsorber can be used up to a maximum cumulative treatment time of 24 h, and regenerable and is stored in sodium acid at 2-8° C. 6,000 ml plasma are usually treated in 12 cycles over 4-5 h. Vascular access is obtained across a central venous catheter in the internal jugular vein or canula insertion into antecubital veins. Two to ten treatments on the following days can performed. The therapy is safe with no serious side effects, which was shown in case reports [75-77]. The increase of CRP concentration during the acute response after AMI correlated significantly with the infarct size in control patients [15]. Patients under CRP apheresis showed smaller infarct sizes and improved left ventricular function and wall motion compared to patients without CRP apheresis [78]. 

The use of CRP apheresis seems efficient for selective CRP depletion from human plasma. Nevertheless, further investigation is required through larger, multicentric studies to elucidate the role of CRP apheresis in the treatment of AMI.   

Heart Transplant Rejection

Thousands of heart transplantations are performed worldwide each year. The outcomes have gradually improved since the first successful heart transplantation since 1967. Nevertheless, long-term survival is still threatened by infection, neoplasia, allograft rejection, or vasculopathy [79]. The most common form of rejection is the cellular rejection mediated by T cells, which is diagnosed through histo-pathologically analysis. Humoral rejection is less frequent but associated with increased graft loss, mortality, and vasculopathy [80]. Allograft vasculopathy is an accelerated of atherosclerosis that occurs in up to 60 percent of transplant recipients within 5 years post-transplantation [79]. Alloreactive immune response begins immediately after blood circulation is re-initiated and the contact with donor organ occurs. During this early phase, the strongest immune response must be expected [81]. In thoracic transplantation, the antibody-mediated rejection (AMR) remains a severe problem. The AMR typically does not respond to conventional therapies, and there are no standard therapy strategies [82, 83]. Immunosuppressants generally affect only cellular signal transfer and are associated with various drug-adverse effects. The introduction of novel immunosuppressive medications reduced the rate of acute allograft rejection but did not improve significantly the long-term graft survival [84]. Important for the antitumoral therapy is the TA such as TPE or IA because with TA performed non-HLA and HLA-ab can be quickly and effectively removed [85]. 

In the year following after heart transplantation, a significant number of patients develop cardiac allograft vasculopathy (CAV) [86]. The pathogenesis of CAV can attribute to initial endothelial injury followed by intima hyperplasia and proliferation of vascular smooth muscle cells. Cardiac allograft vasculopathy is defined as intimal proliferation of 0.5 mm or more [87]. A characteristic of CAV is a diffuse concentric stenosis of allograft coronary arteries due to intimal expansion, or the CAV is defined by the presence of a coronary stenosis of 40 percent or more and/or distal pruning of secondary side branches. The CAV can be diagnosed either by angiography or by intravascular ultrasound, and is induced by immunologic or non-immunologic factors [88, 89]. Vascular endothelial growth factor, a leukocyte mitogen produced by activated endothelial cells and leukocytes, may play a specific role not only in leukocyte trafficking, but also in the augmentation of acute cellular rejection and development of CAV [90]. 

For prevention and treatment of rejection, the therapy includes cyclosporine, azathioprine or mycophenolate mofetil, corticosteroids with or without antilymphocyte antibodies, HMAs and TA [17, 91, 92]. There are many therapy protocols to prevent acute allograft rejection, which include early TPE or IA, bortezomib, a proteasome inhibitor, basiliximab and thymoglobulin, and others [93-95]. All clinically successful AMR treatment protocols include TPE or IA [38 96]. Therapeutic apheresis in heart transplantation rejection is well tolerated, and besides its anti-rejection effects, it also affects has beneficial effects on other systems including oxidized particles, coagulation, CRP, adhesion molecules, plasma viscosity, monocytes, inflammatory HDL particles [86]. 

Extracorporeal photopheresis is also used to manage the heart transplant rejection. The precise mechanism of action of ECP remains unclear. Two explanations are discussed: The first is stimulation of the immune system to destroy clone-specific T cells causing allograft rejection. The second mechanism of action is the induction of antigen-specific immunotolerance via expansion of regulatory T cells [97]. Extracorporeal photopheresis is generally well tolerated with few adverse effects and low infection risk [98]. The European ECP study showed in heart transplantation that ECP can effectively be used to treat different rejection types and to prevent rejection in the modern era of immunosuppression [99]. Extracorporeal photopheresis is an immunomodulatory therapy currently recommended as an adjunctive treatment for the prevention and management of organ rejection in heart transplantation [100].               

In the guidelines on the use of TA of the AAC of the ASFA has the heart transplant rejection for TPE the category II with RG 1C for desensitization, category III with 2C for AMR, and for ECP the category II with RG 2A for prophylaxis or rejection and the category II with RG 1B for treatment of cellular or recurrent rejection [17, 18](Table 1). The extracorporeal methods are qualified for rescue therapy of acute or hyper-acute rejection (81). Nevertheless, future research is required to ascertain the extent to which TA contributes to the survival of heart transplantation. The present discussion does not address other cardiologic diseases, as they are treated by different modalities 

Closing Remark 

It can be concluded that all mentioned cardiologic disease must be treated with TA, Immunosuppression, and/or HMAs. This demand presents a great challenge to physicians, politicians, health organizations, and especially manufactures [101]. The medical supply companies constantly justifying the high costs by pointing to the expensive research and development that is required. All those involved in the healthcare system must strengthen their cooperation in the respect. 

Idiopathic dilated cardiomyopathy is an example of antibody-mediated immune disease. Patients with severe symptoms of IDCM who have failed high doses of conventional therapy and/or have an aggressive and rapidly progressive course of the disorders, must be treated with TPE or IA with immunosuppression and/or HMAs. Coronary heart disease by dyslipoproteinemia still maintains its position at the top morbidity statistics in industrialized nations, if diet and lipid lowering drugs failed, LA and/or PCSK9-inhibitors, and HMA are indicated. Acute myocardial infarction with the acute phase mediator CRP can be treated with CRP apheresis, which is an efficient and selective CRP removal from plasma with improvement of the left ventricular function. In rejection prophylaxis, desensitization, AMR, and cellular or recurrent heart rejection, especially in acute or hyper-acute rejection, TPE, IA or ECP are indicated besides the immunosuppression and/or HMAs. The various TA methods are an immunomodulatory therapy, and recommended as a adjunctive treatment for prevention and management of heart transplant rejection [38].

Well trained and experienced physicians and staff can overcome technically difficulties to complete the procedure without complications [102].  In order to assess the cost-effectiveness of the aforementioned diseases, it is essential to calculate the quotient relevant for cost-effectiveness assessment, defined as the cost of treatment minus the cost saved divided by the improvement in life quality. This must be discussed and calculated precisely by all involved parties [103]. Every effort should be made to delay the progression of acute and chronic disease. Therapeutic apheresis is clearly an important tool in the treatment of many complex conditions both currently and in future [104]. In diseases the treatment with TA must be combined with immunosuppression, IVIG, and/or HMAs, or others. 

The medical progress is advancing and will not be stopped. Since the introduction of hollow fiber membranes, exceptional efforts in research and development have been undertaken in the apheresis sector alone, enabling, for example, the introduction of semi- and selective separation techniques into clinical practice [4]. This is reflected in the numerous national and international specialist congresses, which take place every year. 

Conclusion

Besides conservative therapy, immunosuppression, and/or HMAs, some cardiologic diseases could be treated successfully with TA. All TA techniques described here are all effective and safe. With daily or other day treatment a rapid improvement could be reached. Immunoadsorption with special adsorbers which are binding antibodies that inhibit the β1-adrenergic receptors of the heart muscle and conservative therapy improved severe IDCM. In severe CHD and dyslipoproteinemia LA and lipid lowering such as HMG-CoA-reductase inhibitors and ezetimibe are indicated. In AMI with elevated CRP specific CRP adsorbers remove efficiently CRP and lead to improve survival outcomes. For prevention and treatment of heart transplant rejection, besides immunosuppression, HMAs, TPE, IA, and/or ECP are indicated, and is well tolerated and safe. Well trained and experienced physicians and staff can overcome technically difficulties and complications. However, the costs of TA, especially the hollow fibers and adsorbers, must be decreased, and further multicenter studies must be taken to clarify the TA in the treatment of various cardiologic disease.     

Abbreviations

AAC: Apheresis Application Committee, ASFA: American Society for Apheresis, ACS: Acute coronary syndrome, AMI: acute myocardial infarction, AMR: antibody-mediated rejection, bFGF: basic fibroblast growth factor, CAV: Cardiac allograft vasculopathy,  CHD: coronary heart disease, CRP: C-reactive protein, CVD: cardiovascular disease, DCM: dilated cardiomyopathy, ECP: extracorporeal photopheresis, ED-HF: HDL: high-density lipoprotein, HLA: human leukocyte antigen, HMA: human monoclonal antibody, HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A, IA: Immunoadsorption, IC: immune complexes, IDCM: Idiopathic dilated cardiomyopathy, IS: immunosuppression, IVIG: intravenous immunoglobulin, LA: lipid apheresis, LDL. Low-density lipoprotein, Il-1: interleukin 1, IL-6: interleukin 6, Lp(a):  lipoprotein (a), LVEF: left ventricular election fraction,  NO. nitride oxide, NYHA: New York Heart Association, PAI-1: plasminogen activator inhibitor-1, PCSK9-inhibitor: proprotein convertase subtilisin/kexin type 9 inhibitor, PDGF: platelet derived growth factor, PGI2: prostacyclin, PGH2: prostaglandin H2 RG: recommendation grade, TA: therapeutic apheresis, TNF: tumor necrosis factor, t-PA: tissue plasminogen activator, TPE: therapeutic plasma exchange, VEGF: vascular endothelial growth factor,

References

Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.

img

Virginia E. Koenig

Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.

img

Delcio G Silva Junior

Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.

img

Ziemlé Clément Méda

Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.

img

Mina Sherif Soliman Georgy

We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.

img

Layla Shojaie

The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.

img

Sing-yung Wu

Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.

img

Orlando Villarreal

Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.

img

Katarzyna Byczkowska

Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.

img

Anthony Kodzo-Grey Venyo

Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.

img

Pedro Marques Gomes

Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.

img

Bernard Terkimbi Utoo

This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.

img

Prof Sherif W Mansour

Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.

img

Hao Jiang

As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.

img

Dr Shiming Tang

Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.

img

Raed Mualem

International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.

img

Andreas Filippaios

Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.

img

Dr Suramya Dhamija

Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.

img

Bruno Chauffert

I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!

img

Baheci Selen

"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".

img

Jesus Simal-Gandara

I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.

img

Douglas Miyazaki

We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.

img

Dr Griffith

I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.

img

Dr Tong Ming Liu

I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.

img

Husain Taha Radhi

I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.

img

S Munshi

Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.

img

Tania Munoz

“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.

img

George Varvatsoulias

Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.

img

Rui Tao

Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.

img

Khurram Arshad

Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.

img

Gomez Barriga Maria Dolores

The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.

img

Lin Shaw Chin

Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.

img

Maria Dolores Gomez Barriga

Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.

img

Dr Maria Dolores Gomez Barriga

Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.

img

Dr Maria Regina Penchyna Nieto

Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.

img

Dr Marcelo Flavio Gomes Jardim Filho

Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”

img

Zsuzsanna Bene

Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner

img

Dr Susan Weiner

My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.

img

Lin-Show Chin